Nationwide Efficacy-Safety Study of Nebivolol in Mildly Hypertensive Patients
| Autor: | F. Fici, A. Lichtenthal, W. Mäkel, Ton J. Cleophas, R. Agrawal |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Adrenergic beta-Antagonists Diastole Blood Pressure Essential hypertension Ambulatory Care Facilities World health Nebivolol Heart Rate Germany Internal medicine medicine Humans Benzopyrans Pharmacology (medical) Clinical efficacy Adverse effect Antihypertensive Agents Pharmacology business.industry General Medicine Middle Aged medicine.disease Clinical trial Blood pressure Ethanolamines Hypertension Cardiology Female business medicine.drug |
| Zdroj: | American Journal of Therapeutics. 13:192-197 |
| ISSN: | 1075-2765 |
| Popis: | Nebivolol has been adequately tested in clinical efficacy trials of patients with mild hypertension. Clinical efficacy trials or their meta-analyses did not accurately predict the outcome of subsequent large studies. The primary objective was to assess the efficacy/safety of nebivolol 5-10 mg daily in a nationwide study of patients with mild hypertension. Secondary objectives were (1) to compare efficacy/safety as monotherapy versus add-on therapy and (2) to assess the effect of nebivolol on ISH. This was an open-label, 6-week follow-up study of 6,356 patients with mild hypertension or ISH, as defined by the 1999 World Health Organization guidelines, recruited from 2,700 facilities. Previous monotherapies were continued except for beta-blockers. Results are reported as means+/-SDs. Intention-to-treat analysis is given. A total of 5,740 patients completed the study; of the withdrawals, 90% were lost for follow-up or were noncompliant, 38% were untreated before, 23% had beta-blockers. In the accumulated data, mean systolic and diastolic blood pressures fell by 24+/-14 and 13+/-9 mm Hg (both P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|